AVROBIO Inc

NASDAQ AVRO

Download Data

AVROBIO Inc Net Current Asset Value 2 year CAGR for the quarter ending March 31, 2024: -20.21%

AVROBIO Inc Net Current Asset Value 2 year CAGR is -20.21% for the quarter ending March 31, 2024, a 64.56% change year over year. Net current asset value is a financial metric that represents the excess of a company's current assets over its total liabilities. It is calculated by subtracting the total liabilities from the total current assets of a company. Net current asset value provides insights into the value that would be available to shareholders if the company were to liquidate its current assets and pay off its liabilities. This metric is used to assess the company's liquidity position and the potential value for shareholders in a liquidation scenario. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • AVROBIO Inc Net Current Asset Value for the quarter ending March 31, 2023 was 42,319,000.00, a -69.50% change year over year.
  • AVROBIO Inc Net Current Asset Value for the quarter ending March 31, 2022 was 138,741,000.00, a -39.44% change year over year.
  • AVROBIO Inc Net Current Asset Value for the quarter ending March 31, 2021 was 229,082,000.00, a -9.15% change year over year.
  • AVROBIO Inc Net Current Asset Value for the quarter ending March 31, 2020 was 252,144,000.00, a 144.56% change year over year.
NASDAQ: AVRO

AVROBIO Inc

CEO Mr. Geoff MacKay BSc
IPO Date June 21, 2018
Location United States
Headquarters Building 300, Cambridge, MA, United States, 02139
Employees 13
Sector Healthcare
Industry Biotechnology
Description

AVROBIO, Inc., a clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1 and 3; AVR-RD-01, which is in phase 2 clinical trials for the treatment of Fabry disease; and AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Similar companies

HEPA

Hepion Pharmaceuticals Inc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email